FOXA
39
4
HSIC
50
3
KMI
51
-2
BXP
50
11
COF
59
2
TAP
50
2
RIG
44
4
CNX
69
2
UNM
67
-5
MET
51
14
WM
74
4
CB
60
16
AVB
62
3
AAP
38
3
CTSH
44
3
QCOM
66
-3
SRCL
47
3
PRU
50
5
FCX
61
-2
QRVO
47
-7
FOXA
39
4
HSIC
50
3
KMI
51
-2
BXP
50
11
COF
59
2
TAP
50
2
RIG
44
4
CNX
69
2
UNM
67
-5
MET
51
14
WM
74
4
CB
60
16
AVB
62
3
AAP
38
3
CTSH
44
3
QCOM
66
-3
SRCL
47
3
PRU
50
5
FCX
61
-2
QRVO
47
-7
Financhill
Back

Intra-Cellular Therapies 10K Form

Sell
50

ITCI
Intra-Cellular Therapies

Last Price:
72.36
Seasonality Move:
8.06%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ITCI News And Ratings

See the #1 stock for the next 7 days that we like better than ITCI

ITCI Financial Statistics

Sales & Book Value

Annual Sales: $462.18M
Cash Flow: $-2.06M
Price / Cash Flow: 0
Annual Sales: $6.14
Price / Book: 11.85

Profitability

EPS (TTM): -1.46000
Net Income (TTM): $-139.67M
Gross Margin: $428.43M
Return on Equity: -22.65%
Return on Assets: -19.21%

Intra-Cellular Therapies Earnings Forecast

Key Intra-Cellular Therapies Financial Ratios

  • The Gross Profit Margin over the past 10 years for ITCI is 92.70%.
  • The Selling, General & Administrative Expenses for ITCI have been equal to 88.68% of Gross Profit Margin.
  • The Research & Development expenses have been 38.98% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Intra-Cellular Therapies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ITCI
CUSIP: 46116X
Website: intracellulartherapies.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.41
Quick Ratio: 4.95

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 79.95

ITCI Technical Analysis vs Fundamental Analysis

Sell
50
Intra-Cellular Therapies (ITCI) is a Sell

Is Intra-Cellular Therapies a Buy or a Sell?